

Investment Research

Buy

Recommendation unchanged

Share price: EUR 18.80

closing price as of 10/11/2011

Target price: EUR 31.50

Target Price unchanged

Reuters/Bloomberg EUCG.DE/EUC GY

Daily avg. no. trad. sh. 12 mth	19,877
Daily avg. trad. vol. 12 mth (m)	0.41
Price high 12 mth (EUR)	23.29
Price low 12 mth (EUR)	17.50
Abs. perf. 1 mth	-1.3%
Abs. perf. 3 mth	5.9%
Abs. perf. 12 mth	-12.6%

Market capitalisation (EURm)	96
Current N° of shares (m)	5
Free float	100%

Key financials (EUR)	12/10	12/11e	12/12e
Sales (m)	204	295	325
EBITDA (m)	25	32	37
EBITDA margin	12.1%	10.8%	11.3%
EBIT (m)	20	25	29
EBIT margin	9.9%	8.4%	8.9%
Net Profit (adj.)(m)	11	14	16
ROCE	9.0%	8.1%	9.0%
Net debt/(cash) (m)	51	82	78
Net Debt Equity	0.6	0.8	0.7
Net Debt/EBITDA	2.0	2.6	2.1
Int. cover(EBITDA/Fin.int)	8.5	8.6	7.6
EV/Sales	0.8	0.7	0.6
EV/EBITDA	6.6	6.3	5.3
EV/EBITDA (adj.)	6.6	6.3	5.3
EV/EBIT	8.2	8.0	6.8
P/E (adj.)	9.1	6.9	6.0
P/BV	1.2	1.0	0.9
OpFCF yield	4.6%	-12.8%	9.1%
Dividend yield	5.9%	5.9%	6.4%
EPS (adj.)	2.38	2.73	3.13
BVPS	18.42	19.03	21.06
DPS	1.10	1.10	1.20



Source: Factset

For company description please see summary table footnote

Strong 3Q11 reporting and positive outlook re-affirmed Confirm 'Buy' rating and PT of EUR 31.5

EUCA released a strong set of 3Q11 figures that exceeded our forecast in every aspect. The positive outlook was re-affirmed and our estimates for next year are probably very conservative. We confirm our 'Buy' rating and PT of EUR 31.5.

- ✓ EUCA reported 3Q11 sales of EUR 92.3m which clearly exceeded our expectation of EUR 81.5m by 13%. EUCA stated that it had strong organic growth of 30% yoy which means that acquired units (mainly telent) contributed c. EUR 25m) to this growth. Thanks to the good top line, the EBIT came in also strong. Here, the company reported an operating profit of EUR 6.3m which corresponds to a margin of 6.8%. Our forecast stood at only EUR 4.1m and 5.1%, respectively, as we expected a higher margin dilution from the acquired entities. The net result was said to be EUR 2.9m which is better than our projection by about EUR 1m. The EPS came in at EUR 0.58 (equinet: EUR 0.37).

3Q11 review

EUR m	9M11a	9M11e	delta	9M10	yoy	3Q11a	3Q11e	delta	3Q10	yoy
Order intake	245.4	241.1	2%	154.0	59%	89.3	85.0	5%	45.5	96%
Sales	220.6	209.8	5%	149.8	47%	92.3	81.5	13%	53.6	72%
EBIT	14.9	12.8	17%	10.3	45%	6.3	4.1	52%	3.2	97%
EBIT margin	6.8%	6.1%	+70bp	6.9%	-10bp	6.8%	5.1%	+170bp	5.9%	+90bp
Net result	7.8	6.8	15%	5.6	40%	3.0	1.9	54%	1.5	94%
EPS [EUR]	1.53	1.32	16%	1.17	31%	0.58	0.37	56%	0.33	77%

Source: company data, equinet estimates

- ✓ The order intake was strong as well and achieved EUR 245.4m after nine months (Book-to-bill of 1.11). Here, our forecast stood at EUR 241.1m. Order backlog was at EUR 174m, providing a good 6 months visibility.
- ✓ EUCA repeated the long-term strategic margin outlook of 8-11%. For FY11, the company confirmed the EUR 280-300m range, but stated to clearly target the upper end. As regards the EBIT forecast, EUCA plans for a 7.5-8.5% margin range. The lower end might be reached as probably, some integration cost and PPA will be booked in 4Q11. In the report we found that for the last quarter, EUCA sees order intake stable or slightly increasing.
- ✓ We now speculate that even the EUR 300m for this year's top line could be a bit conservative after the strong organic growth and the good performance telent must have had so far. We consider the FY11 EBIT outlook to be in line with our projection of EUR 24.7m as we did not account for PPA / one-off cost so far. Please consider that management guides conservatively.
- ✓ As expected, there were no statements about FY12, but here, please consider that telent was consolidated as of June 7, 2011. This means that the respective revenue recognition for a full year for the first time should lead to additional sales of c. EUR 40m alone. Taking this into account, we note that our FY12 top line forecast of EUR 325m is probably very conservative, which was also underlined by management statements today.

Analyst(s): Adrian Pehl, CFA

+49 69 58997 438 adrian.pehl@equinet-ag.de



- ✓ EUCA has announced a capital increase comprising c. 1.5m new shares. We will include this transaction into our model after it is concluded as well as any changes from an improved outlook. According to our calculations **EUCA should at least be able to generate a FY12 EPS of c. EUR 2.5 next year after dilution (P/E'12 of 7.3x)**. We confirm our DCF/multiple based PT of EUR 31.5 for the time being as well as our 'Buy' recommendation.

Discounted Cash Flow model

EUR m	Phase I					Phase II					Phase III
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Sales	295.0	325.0	342.5	356.2	368.7	379.7	391.1	402.9	414.9	427.4	435.9
Sales growth	44.9%	10.2%	5.4%	4.0%	3.5%	3.0%	3.0%	3.0%	3.0%	3.0%	2.0%
EBIT	24.7	28.9	32.6	34.7	36.2	33.7	34.7	35.8	36.8	37.9	38.9
EBIT margin	8.4%	8.9%	9.5%	9.7%	9.8%	8.9%	8.9%	8.9%	8.9%	8.9%	8.9%
Tax	(6.3)	(7.2)	(8.3)	(8.9)	(9.4)	(8.6)	(9.0)	(9.3)	(9.7)	(10.0)	(10.0)
Tax rate	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%	29.5%
NOPAT	18.4	21.7	24.3	25.8	26.8	25.1	25.8	26.4	27.2	27.9	28.8
Depreciation	7.0	7.9	8.4	8.9	9.3	10.1	10.4	10.7	11.0	11.4	11.4
in % of Sales	2.4%	2.4%	2.4%	2.5%	2.5%	2.7%	2.7%	2.7%	2.7%	2.7%	2.6%
Capex	(26.7)	(10.1)	(10.6)	(11.0)	(11.4)	(11.6)	(11.9)	(12.3)	(12.7)	(13.0)	(11.6)
in % of Sales	9.0%	3.1%	3.1%	3.1%	3.1%	3.1%	3.1%	3.1%	3.1%	3.1%	2.7%
Provision delta	13.6	0.3	0.3	0.3	0.3	0.1	0.1	0.1	0.1	0.1	0.3
in % of Sales	4.6%	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
NWC delta	(38.3)	(6.5)	(1.7)	(3.8)	(3.5)	(3.1)	(3.2)	(3.3)	(3.4)	(3.5)	(0.5)
in % of Sales	-13.0%	-2.0%	-0.5%	-1.1%	-0.9%	-0.8%	-0.8%	-0.8%	-0.8%	-0.8%	-0.1%
Other current assets delt	2.2	0.1	0.2	0.1	0.2	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.2
in % of Sales	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
Free Cash Flow	-23.7	13.5	20.9	20.2	21.6	20.5	21.1	21.6	22.2	22.8	28.7
FCF growth	nm	-56.8%	55.2%	-3.3%	7.0%	-5.0%	2.6%	2.6%	2.7%	2.7%	26.1%
Present Value FCF	-23.4	12.1	17.0	14.9	14.5	12.5	11.6	10.8	10.1	9.4	145.7

PV Phase I	35.0	Mcap	93.5	Targ. equity ratio	83.5%
PV Phase II	54.5	Risk premium	4.00%	Beta	1.62
PV Phase III	145.7	Risk free rate	4.50%	WACC	10.15%

Total present value	235.3						
+ capital increase/share buy back	0.0						
+ associates & other financial assets	1.0						
- market value of minorities	7.2						
+ cash and liquid assets	9.9						
- interest bearing debt*	62.1						
Implied Mcap	176.8						
Number of shares	5.1						
Implied value per share	34.49						
		Sensitivity Analysis	Growth rate Phase III				
			1.0%	1.5%	2.0%	2.5%	3.0%
		9.64%	34.52	36.23	38.18	40.39	42.94
		9.89%	32.90	34.49	36.27	38.30	40.62
		10.15%	31.38	32.85	34.49	36.35	38.47
		10.40%	29.95	31.31	32.82	34.53	36.47
		10.65%	28.59	29.85	31.25	32.83	34.61

* Including pension provisions

Source: equinet

Peer Group Valuation

	P/E 2011	P/E 2012	P/E 2013	EV/EBITDA 2011	EV/EBITDA 2012	EV/EBITDA 2013	EV/EBIT 2011	EV/EBIT 2012	EV/EBIT 2013
ADVA AG OPTICAL NETWORKING	17.0	14.3	10.4	5.0	4.1	3.2	12.9	8.3	5.9
AMEC PLC	13.2	11.5	10.3	7.7	6.7	6.0	8.7	7.5	6.7
BECHTLE AG	8.9	8.9	7.9	5.1	5.1	4.7	6.2	6.2	5.6
BELDEN INC	13.6	11.5	9.3	7.9	6.9	5.9	10.0	8.8	nm
HUBER+SUHNER AG	16.0	17.5	14.5	6.6	7.1	6.5	9.4	10.7	9.3
IMTECH	9.5	8.3	7.8	6.4	5.3	4.6	7.9	6.4	5.6
KONTRON	10.9	12.7	11.4	5.0	5.1	4.4	7.6	8.3	7.1
LEGRAND SA	12.2	11.8	11.1	7.7	7.5	7.1	9.3	9.0	8.5
MOLEX INC	14.0	12.4	11.6	4.6	4.3	4.0	7.2	6.4	5.9
MEDIAN	13.2	11.8	10.4	6.4	5.3	4.7	8.7	8.3	6.3
EJROMICRON AG	6.9	6.0	5.2	6.1	5.2	4.7	7.8	6.7	5.9
THEOR. VALUATION PER SHARE OF EUROMICRON	36.0	37.0	37.8	21.1	19.5	19.0	23.1	28.2	21.2

Sources: Thomson Financial, Bloomberg, ESN and equinet estimates

Euromicron AG: Summary tables

PROFIT & LOSS (EURm)	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
Sales	165	180	204	295	325	343
Cost of Sales & Operating Costs	-146	-160	-179	-263	-288	-302
Non Recurrent Expenses/Income	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	18.8	19.9	24.7	31.7	36.8	41.0
EBITDA (adj.)*	18.8	19.9	24.7	31.7	36.8	41.0
Depreciation	-1.2	-1.6	-2.2	-5.5	-5.9	-6.2
EBITA	17.6	18.3	22.6	26.2	30.9	34.8
EBITA (adj)*	17.6	18.3	22.6	26.2	30.9	34.8
Amortisations and Write Downs	-1.6	-2.0	-2.4	-1.5	-2.0	-2.2
EBIT	16.0	16.4	20.1	24.7	28.9	32.6
EBIT (adj.)*	16.0	16.4	20.1	24.7	28.9	32.6
Net Financial Interest	-4.0	-3.0	-2.9	-3.7	-4.9	-5.0
Other Financials	0.0	0.0	0.0	0.0	0.0	0.0
Associates	0.0	0.0	0.0	0.0	0.0	0.0
Other Non Recurrent Items	0.0	0.0	0.0	0.0	0.0	0.0
Earnings Before Tax (EBT)	12.0	13.4	17.2	21.0	24.0	27.7
Tax	-3.3	-3.1	-5.1	-6.3	-7.2	-8.3
<i>Tax rate</i>	<i>27.5%</i>	<i>23.4%</i>	<i>29.5%</i>	<i>30.0%</i>	<i>30.0%</i>	<i>30.0%</i>
Discontinued Operations	0.0	0.0	0.0	0.0	0.0	0.0
Minorities	-0.7	-0.5	-0.7	-0.7	-0.8	-0.8
Net Profit (reported)	8	10	11	14	16	19
Net Profit (adj.)	8	10	11	14	16	19
CASH FLOW (EURm)	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
Cash Flow from Operations before change in NWC	12.8	13.4	16.1	36.0	25.4	28.6
Change in Net Working Capital	-9.3	3.2	-6.8	-38.3	-6.5	-1.7
Cash Flow from Operations	3.5	16.6	9.3	-2.3	18.9	27.0
Capex	-4.5	-6.5	-4.6	-10.0	-10.1	-10.6
Net Financial Investments	-9.1	-6.6	-6.3	-16.7	0.0	0.0
Free Cash Flow	-10.1	3.5	-1.6	-29.0	8.8	16.4
Dividends	-3.7	-4.5	-4.5	-5.3	-5.6	-6.2
Other (incl. Capital Increase & share buy backs)	-13.7	0.1	13.7	2.8	0.9	1.0
Change in Net Debt	-27	-1	8	-31	4	11
NOPLAT	12	13	14	17	20	23
BALANCE SHEET & OTHER ITEMS (EURm)	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
Net Tangible Assets	9.0	10.9	11.6	15.1	16.0	17.0
Net Intangible Assets (incl. Goodwill)	82.5	90.1	95.8	112	113	114
Net Financial Assets & Other	0.1	1.3	1.0	1.0	1.0	1.0
Total Fixed Assets	91.5	102	108	128	130	132
Net Working Capital	45.9	42.6	49.4	87.8	94.3	95.9
Group Shareholders Equity	66.0	71.4	89.3	98.7	110	123
<i>o/w own Shareholders Equity</i>	<i>65.8</i>	<i>71.1</i>	<i>88.8</i>	<i>97.5</i>	<i>108</i>	<i>120</i>
Net Debt	57.2	58.2	50.6	82.0	77.9	66.8
Provisions	7	7	7	22	24	26
Other Net Liabilities or Assets	7	8	10	13	13	13
GROWTH & MARGINS	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
<i>Sales growth</i>	<i>20.6%</i>	<i>9.1%</i>	<i>13.4%</i>	<i>44.9%</i>	<i>10.2%</i>	<i>5.4%</i>
EBITDA (adj.)* growth	23.8%	5.6%	24.3%	28.4%	15.8%	11.5%
<i>EBITA (adj.)* growth</i>	<i>28.3%</i>	<i>3.9%</i>	<i>23.2%</i>	<i>16.3%</i>	<i>17.8%</i>	<i>12.5%</i>
<i>EBIT (adj.)* growth</i>	<i>33.2%</i>	<i>2.3%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>16.7%</i>	<i>12.9%</i>
<i>Net Profit growth</i>	<i>15.2%</i>	<i>21.2%</i>	<i>17.2%</i>	<i>22.2%</i>	<i>14.6%</i>	<i>15.6%</i>
EPS adj. growth	16.8%	22.1%	9.4%	15.0%	14.6%	15.6%
<i>DPS adj. growth</i>	<i>25.3%</i>	<i>0.0%</i>	<i>10.0%</i>	<i>0.0%</i>	<i>9.1%</i>	<i>8.3%</i>
EBITDA margin	11.4%	11.1%	12.1%	10.8%	11.3%	12.0%
<i>EBITDA (adj.)* margin</i>	<i>11.4%</i>	<i>11.1%</i>	<i>12.1%</i>	<i>10.8%</i>	<i>11.3%</i>	<i>12.0%</i>
<i>EBITA margin</i>	<i>10.7%</i>	<i>10.2%</i>	<i>11.1%</i>	<i>8.9%</i>	<i>9.5%</i>	<i>10.2%</i>
<i>EBITA (adj.)* margin</i>	<i>10.7%</i>	<i>10.2%</i>	<i>11.1%</i>	<i>8.9%</i>	<i>9.5%</i>	<i>10.2%</i>
<i>EBIT margin</i>	<i>9.7%</i>	<i>9.1%</i>	<i>9.9%</i>	<i>8.4%</i>	<i>8.9%</i>	<i>9.5%</i>
<i>EBIT (adj.)* margin</i>	<i>9.7%</i>	<i>9.1%</i>	<i>9.9%</i>	<i>8.4%</i>	<i>8.9%</i>	<i>9.5%</i>

Euromicron AG: Summary tables

RATIOS	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
Net Debt/Equity	0.9	0.8	0.6	0.8	0.7	0.5
Net Debt/EBITDA	3.0	2.9	2.0	2.6	2.1	1.6
Interest cover (EBITDA/Fin.interest)	4.8	6.7	8.5	8.6	7.6	8.3
Capex/D&A	156.5%	185.5%	99.4%	142.9%	127.7%	126.7%
Capex/Sales	2.7%	3.6%	2.2%	3.4%	3.1%	3.1%
NWC/Sales	27.9%	23.7%	24.3%	29.8%	29.0%	28.0%
ROE (average)	11.9%	14.3%	14.3%	15.0%	15.6%	16.3%
ROCE (adj.)	8.5%	8.7%	9.0%	8.1%	9.0%	10.0%
WACC	10.4%	10.4%	10.4%	10.4%	10.4%	10.4%
ROCE (adj.)/WACC	0.8	0.8	0.9	0.8	0.9	1.0
PER SHARE DATA (EUR)***	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
Average diluted number of shares	4.5	4.5	4.8	5.1	5.1	5.1
EPS (reported)	1.78	2.17	2.38	2.73	3.13	3.62
EPS (adj.)	1.78	2.17	2.38	2.73	3.13	3.62
BVPS	14.51	15.78	18.42	19.03	21.06	23.48
DPS	1.00	1.00	1.10	1.10	1.20	1.30
VALUATION	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
EV/Sales	0.7	0.8	0.8	0.7	0.6	0.5
EV/EBITDA	6.1	6.8	6.6	6.3	5.3	4.5
EV/EBITDA (adj.)*	6.1	6.8	6.6	6.3	5.3	4.5
EV/EBITA	6.5	7.4	7.3	7.6	6.3	5.3
EV/EBITA (adj.)*	6.5	7.4	7.3	7.6	6.3	5.3
EV/EBIT	7.2	8.3	8.2	8.0	6.8	5.7
EV/EBIT (adj.)*	7.2	8.3	8.2	8.0	6.8	5.7
P/E (adj.)	5.9	7.2	9.1	6.9	6.0	5.2
P/BV	0.7	1.0	1.2	1.0	0.9	0.8
Total Yield Ratio	12.2%	6.4%	2.3%	5.9%	6.4%	6.9%
EV/CE	0.8	0.9	1.0	0.9	0.9	0.8
OpFCF yield	-2.0%	14.3%	4.6%	-12.8%	9.1%	17.0%
OpFCF/EV	-0.8%	7.4%	2.9%	-6.2%	4.5%	8.9%
Payout ratio	56.2%	46.1%	46.3%	40.3%	38.3%	35.9%
Dividend yield (gross)	9.6%	6.4%	5.9%	5.9%	6.4%	6.9%
EV AND MKT CAP (EURm)	12/2008	12/2009	12/2010	12/2011e	12/2012e	12/2013e
Price** (EUR)	10.5	15.6	21.6	18.8	18.8	18.8
Outstanding number of shares for main stock	4.5	4.5	4.8	5.1	5.1	5.1
Total Market Cap	47.4	70.2	104	96.4	96.4	96.4
Net Debt	57.2	58.2	50.6	82.0	77.9	66.8
<i>o/w Cash & Marketable Securities (-)</i>	<i>-11.2</i>	<i>-9.8</i>	<i>-9.9</i>	<i>-21.5</i>	<i>-25.6</i>	<i>-33.4</i>
<i>o/w Gross Debt (+)</i>	<i>68.5</i>	<i>68.0</i>	<i>60.5</i>	<i>104</i>	<i>104</i>	<i>100</i>
Other EV components	10	7	10	20	21	22
Enterprise Value (EV adj.)	115	136	164	199	195	185

Source: Company, Equinet Bank estimates.

Notes

* Where EBITDA (adj.) or EBITA (adj) or EBIT (adj.) = EBITDA (or EBITA or EBIT) +/- Non Recurrent Expenses/Income

** Price (in local currency): Fiscal year end price for Historical Years and Current Price for current and forecasted years

*** EPS (adj.) diluted = Net Profit (adj.) / Avg DIL. Ord. (+ Ord. equivalent) Shs. EPS (reported) = Net Profit reported / Avg DIL. Ord. (+ Ord. equivalent) Shs.

Sector: Electronic & Electrical Equipment/Electrical Components & Equipment

Company Description: The euromicron Group with its extensive network of branch offices in Germany is a system house that is active in the future market of network and fiber optics technology. euromicron develops, produces and distributes network components based on copper, glass fiber and wireless technology and plans, implements and maintains communications, information and security networks for all applications.

Recommendations and Disclosures

Coverage	Analyst	Target	Rating	Disc.	Coverage	Analyst	Target	Rating	Disc.
4SCAG	Aubéry	3.60	Buy	2/3	IntegralsAG	Schäfer	6.75	Hold	2/3
Aareal Bank	Häßler	20.00	Buy		Interseroh	Schäfer	50.00	Buy	2/3
Adpepper	Pehl	1.80	Buy	2/3	Itelligence	Demidova	8.80	Buy	2/3/5
adidas	Faust	64.00	Buy		IVG Immobilien AG	Rothenbacher	4.00	Buy	
Advanced Vision Technology	Aubéry	5.00	Buy	2/3	K+S AG	Schäfer	57.00	Buy	
Aixtron	Pehl	9.00	Reduce	2/3	KHD HUMBOLDT WEDAG INTERNATIONAL	Schuldt	7.60	Buy	
Allianz	Häßler	82.00	Accumulate		Kontron	Pehl	7.00	Buy	
Analytik Jena	Demidova	9.50	Accumulate	7	KronesAG	Schmidt	35.00	Reduce	
Augusta Technologie	Pehl	25.00	Buy	7	KTGAgrar	Schäfer	16.00	Accumulate	2/3/5
BASF	Demidova	72.00	Buy		KUKA	Schäfer	18.00	Hold	
BAUER AG	Schmidt	24.00	Accumulate		LANXESS	Demidova	59.00	Buy	
Bayer	Possienke	50.00	Accumulate		Leoni	Schuldt	41.00	Buy	
BayWa	Schäfer	33.00	Accumulate	5	Linde	Demidova	130.00	Accumulate	
BB Biotech	Aubéry	62.00	Buy	2/7	Loewe	Faust	6.00	Hold	2
Beiersdorf	Aubéry	42.00	Hold		Logwin	Rothenbacher	1.60	Buy	2/3/5
Berentzen	Faust	7.00	Buy	2/3	LPKF LASER & ELECTRONICS	Schuldt	14.00	Hold	
Beta Systems Software	Schuldt	2.10	Hold	2/3	Lufthansa	Rothenbacher	12.00	Accumulate	
Bilfinger Berger	Faust	83.00	Buy		MAN	Schuldt	76.00	Buy	
Biopetrol Industries	Schäfer	0.60	Sell	2/3	MAX Automation AG	Schmidt	4.20	Accumulate	2/3/5
Biotest	Possienke	49.00	Buy	2/3	Medion	Faust	13.00	Hold	
BMW	Schuldt	63.00	Accumulate		Merck	Possienke	63.00	Hold	
Carl Zeiss Meditec	Aubéry	16.00	Accumulate		MLP	Häßler	6.00	Accumulate	
Celesio	Possienke	15.00	Buy		Mobotix AG	Pehl	71.00	Buy	2/3
Cenit	Pehl	7.00	Buy	2/3	Morphosys	Aubéry	35.00	Buy	
comdirect	Häßler	8.50	Accumulate		MTU	Pehl	60.00	Buy	2
Commerzbank	Häßler	2.20	Buy		Munich Re	Häßler	100.00	Hold	
Continental	Schuldt	57.00	Hold		Nanogate AG	Demidova	22.00	Buy	2/3/5
DAB Bank	Häßler	3.40	Hold		Pfeiffer Vacuum	Pehl	76.00	Accumulate	
Daimler AG	Schuldt	49.00	Buy		Phoenix Solar	Freudenreich	6.00	Hold	
Daldrup & Soehne	Schäfer	23.00	Accumulate	2/3/5	Porsche	Schuldt	38.00	Reduce	
Demag Cranes	Schmidt	45.50	Hold	2	Postbank	Häßler	20.00	Hold	
Derby Cycle	Faust	28.00	Buy	2/3/4/5	PSI	Schäfer	18.00	Hold	2
Deutsche Bank	Häßler	40.00	Buy		Puma	Faust	220.00	Hold	
Deutsche Biogas	Schäfer	14.00	Buy	2/3/4/5	Rheinmetall	Pehl	45.00	Hold	
Deutsche Boerse	Häßler	48.00	Accumulate		Rhoen-Klinikum	Possienke	19.00	Buy	
Deutsche EuroShop	Rothenbacher	27.50	Hold		RWE	Schäfer	38.00	Hold	
Deutsche Forfait	Häßler	5.50	Buy	2/3	RIB Software	Rothenbacher	8.50	Buy	2/3/4
Deutsche Post	Rothenbacher	15.00	Buy		SAF-HOLLAND	Schuldt	5.60	Buy	7
Deutsche Telekom	Pehl	11.00	Accumulate		Salzgitter	Freudenreich	53.00	Accumulate	
DNICK Holding plc	Freudenreich	13.00	Buy	2/3	Schuler AG	Schuldt	11.60	Buy	2/3
Douglas Holding	Faust	35.00	Buy		Seven Principles AG	Pehl	11.00	Buy	2/3/5
Drägerwerk	Aubéry	80.00	Hold		Singulus Technologies	Freudenreich	3.20	Hold	4/5
E.ON	Schäfer	20.00	Accumulate		SKW Stahl	Possienke	23.00	Buy	
EringKlinger	Schuldt	21.00	Accumulate		SMA Solar Technology	Freudenreich	50.00	Hold	
Epigenomics AG	Aubéry	13.00	Buy	2/3	SMT SCHARF AG	Schmidt	22.00	Buy	2/3
Euromicron AG	Pehl	31.50	Buy	2/3/5	Solar-Fabrik	Freudenreich	3.60	Buy	2/3
Fielmann	Possienke	75.00	Hold		SolarWorld	Freudenreich	4.10	Hold	
Fraport	Rothenbacher	53.00	Accumulate		Solutronic	Freudenreich	Under review	Not rated	2/3/4/5
Freenet	Pehl	11.00	Buy	2	Stada	Possienke	20.00	Hold	
Fresenius	Aubéry	76.00	Hold		SuessMicroTec	Pehl	10.50	Buy	2/3/5
Fresenius Medical Care	Aubéry	56.00	Accumulate		Sunways	Freudenreich	2.10	Hold	2/3/5
Fuchs Petrolub	Demidova	38.00	Hold		Symrise AG	Demidova	21.00	Accumulate	
GEA Group	Schmidt	26.00	Buy		ThyssenKrupp	Freudenreich	32.00	Hold	
Gerrheimer AG	Aubéry	36.00	Buy		Tognum	Schmidt	26.00	Hold	2
Gesco	Schmidt	75.00	Buy	2/3	TUI	Rothenbacher	5.00	Hold	
GFT Technologies	Schuldt	4.60	Buy	2/3	United Internet	Pehl	14.00	Accumulate	
Gildemeister	Schmidt	16.00	Buy		VBH Holding	Faust	4.00	Hold	2/3
Grenkeleasing AG	Häßler	40.00	Hold		VIB Vermoegen	Rothenbacher	11.00	Buy	
Hannover Re	Häßler	36.00	Hold		Volkswagen	Schuldt	145.00	Accumulate	
Heidelberger Druck	Schmidt	1.05	Sell		Vossloh	Schmidt	60.00	Sell	
Henkel	Demidova	46.00	Hold		Washtec	Schuldt	14.00	Buy	
HHLA	Rothenbacher	27.00	Buy		Wacker Chemie	Freudenreich	82.00	Hold	
Hochtief	Faust	70.00	Buy		Willex	Aubery	7.00	Buy	2/3/5
Hornbach Holding	Possienke	124.00	Buy		Wincor Nixdorf	Pehl	39.00	Hold	2
Hugo Boss	Hugo Boss	75.00	Hold						
HYPOPORT AG	Häßler	13.00	Buy						
i:FAOAG	Rothenbacher	15.00	Buy	2/3					

Source: equinet Recommendations

Notice according to § 34 b (German) Securities Trading Act (“Wertpapierhandelsgesetz”)

This document is issued by Equinet Bank AG (“Equinet Bank”). It has been prepared by its authors independently of the Company, and none of Equinet Bank, the Company or its shareholders has independently verified any of the information given in this document.

Equinet Bank possesses relations to the covered companies as detailed in the table on the previous page. Additional information and disclosures will be made available upon request and/or can be looked up on our website <http://www.Equinet Bank-ag.de>

- 1 - Equinet Bank and/or its affiliate(s) hold(s) more than 5% of the share capital of this company calculated under computational methods required by German law.
- 2 - Equinet Bank acts as a designated sponsor for this company, including the provision of bid and ask offers. Therefore, we regularly possess shares of the company in our proprietary trading books. Equinet Bank receives a commission from the company for the provision of the designated sponsor services.
- 3 – The designated sponsor services include a contractually agreed provision of research services.
- 4 – Within the last twelve months, Equinet Bank was involved as a lead or co-lead manager in the public offering of securities which are/whose issuer is the subject of this report.
- 5 – Within the last twelve months, Equinet Bank and/or its affiliate(s) provided investment banking- and/or other consultancy services for this company and/or it's shareholders.
- 6 - Equinet Bank and/or its affiliate(s) has/have other substantial financial interests in relation to this issuer.
- 7 – Equinet Bank has entered into an agreement with this company about the preparation of research reports and – in return - receives a compensation.

Companies of the Equinet Bank group and/or its directors, officers and employees or clients may take positions in, and may make purchases and/or sales as principal or agent in the securities or related financial instruments discussed in our reports. The Equinet Bank group may provide investment banking and other services to and/or serve as directors of the companies referred to in our reports.

In compliance with Para 5 Sec. 4 of the Ordinance on the Analysis of Financial Instruments (FinAnV) Equinet Bank has realized additional internal and organizational measures, such as specific research guidelines, to prevent or manage conflicts of interest.

Neither the company nor its employees are allowed to receive donations from third parties with a special interest in the content of the analysis.

The salary of the research analysts of Equinet Bank AG does not depend on the investment banking transactions of the company. Nevertheless, this does not rule out the payment of a bonus which depends on the overall financial performance of the bank.

Particular care is taken that the individual performance of each research analyst of Equinet Bank AG is not being assessed by a manager of another business division with similar or same interests.

To assure a highest degree of transparency Equinet Bank AG regularly provides - on a quarterly basis – a summary according to Para 5 Sec. 4 No. 3 of the Ordinance on the Analysis of Financial Instruments (FinAnV). It informs about the overall analysts recommendations and sets them in a relationship to those companies, for which Equinet Bank provided investment banking services within the last twelve months. This summary is published via our website <http://www.Equinet Bank-ag.de>.

Furthermore, we refer to our conflict of interest policy as well as the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) provided in the download area of our website <http://www.Equinet Bank-ag.de>.

Remarks

Recommendation System

- Buy - The stock is expected to generate a total return of over 20% during the next 12 months time horizon.
- Accumulate - The stock is expected to generate a total return of 10% to 20% during the next 12 months time horizon.
- Hold - The stock is expected to generate a total return of 0% to 10% during the next 12 months time horizon
- Reduce - The stock is expected to generate a total return of 0 to -10% during the next 12 months time horizon
- Sell - The stock is expected to generate a total return below -10% during the next 12 months time horizon

Basis of Valuation

Equinet Bank uses for valuation purposes primarily DCF-Valuations and Sum-Of-The-Parts-Valuations as well as peer group comparisons.

Share prices

Share prices in this analysis are the German closing prices of the last trading day before the publication.

Sources

Equinet Bank has made any effort to carefully research all information contained in the analysis. The information on which the analysis is based has been obtained from sources which we believe to be reliable such as, for example, Reuters, Bloomberg and the relevant press as well as the company which is the subject of the analysis. Only that part of the research note is made available to the issuer, who is the subject of the analysis, which is necessary to properly reconcile with the facts. Should this result in considerable changes a reference is made in the research note.

Actualizations

Opinions expressed in this analysis are our current opinions as of the issuing date indicated on this document. We do not commit ourselves in advance to whether and in which intervals updates are made.

DISCLAIMER

THE PREPARATION OF THIS DOCUMENT IS SUBJECT TO REGULATION BY GERMAN LAW. THIS DOCUMENT IS BEING SUPPLIED TO YOU SOLELY IN YOUR CAPACITY AS A PROFESSIONAL INSTITUTIONAL INVESTOR FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. NEITHER THIS DOCUMENT NOR ANY COPY OF IT MAY BE TAKEN OR TRANSMITTED INTO AUSTRALIA, CANADA OR JAPAN OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN OR TO ANY RESIDENT THEREOF.

THE DELIVERY OF THIS RESEARCH REPORT TO U.S. PERSONS IN THE UNITED STATES OF AMERICA IS MADE BY AND UNDER THE RESPONSIBILITY OF ESN NA, INC. (REGISTERED WITH THE SEC). THIS RESEARCH REPORT IS ONLY INTENDED FOR PERSONS WHO QUALIFY AS MAJOR U.S. INSTITUTIONAL INVESTORS, AS DEFINED IN SECURITIES EXCHANGE ACT RULE 15A-6, AND DEAL WITH ESN NA, INC. HOWEVER, THE DELIVERY OF THIS RESEARCH REPORT OR SUMMARY TO ANY U.S. PERSON SHALL NOT BE DEEMED A RECOMMENDATION OF ESN NA, INC. TO EFFECT ANY TRANSACTIONS IN THE SECURITIES DISCUSSED HEREIN OR AN ENDORSEMENT OF ANY OPINION EXPRESSED HEREIN. ESN NA, INC. MAY FURNISH UPON REQUEST ALL INVESTMENT INFORMATION AVAILABLE TO IT SUPPORTING ANY RECOMMENDATIONS MADE IN THIS RESEARCH REPORT. ALL TRADES WITH U.S. RECIPIENTS OF THIS RESEARCH SHALL BE EXECUTED THROUGH ESN NA, INC.

THIS DOCUMENT IS FOR DISTRIBUTION IN THE U.K. ONLY TO PERSONS WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") OR (ii) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, NAMELY HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT MUST NOT BE ACTED ON OR RELIED UPON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS DOCUMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THE DISTRIBUTION OF THIS DOCUMENT IN OTHER JURISDICTIONS OR TO RESIDENTS OF OTHER JURISDICTIONS MAY ALSO BE RESTRICTED BY LAW, AND PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, ANY SUCH RESTRICTIONS. BY ACCEPTING THIS REPORT YOU AGREE TO BE BOUND BY THE FOREGOING INSTRUCTIONS. YOU SHALL INDEMNIFY EQUINET BANK AGAINST ANY DAMAGES, CLAIMS, LOSSES, AND DETRIMENTS RESULTING FROM OR IN CONNECTION WITH THE UNAUTHORIZED USE OF THIS DOCUMENT.

This report is for informational purposes only and has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: readers must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.

The information herein is believed by Equinet Bank to be reliable and has been obtained from sources believed to be reliable, but Equinet Bank makes no representation as to the accuracy or completeness of such information. The information given in this report is subject to change without notice; it may be incomplete or condensed and it may not contain all material information concerning the Company. Opinions expressed herein may differ or be contrary to opinions expressed by other business areas of the Equinet Bank group as a result of using different assumptions and criteria. Equinet Bank is under no obligation to update or keep the information current. Equinet Bank provides data concerning the future development of securities in the context of its usual research activity. However, if a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the price or value of, or the income derived from, the financial instrument, and such investor effectively assumes currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments described in this report, either directly or indirectly, may rise or fall. Furthermore, past performance is not necessarily indicative of future results. Neither the author nor Equinet Bank accepts any liability whatsoever for any loss howsoever arising from any use of this publication or its contents or otherwise arising in connection herewith, except as provided for under applicable regulations.

Equinet Bank shall only be liable for any damages intentionally caused or which result from any gross negligence of Equinet Bank. Further Equinet Bank shall be liable for the breach of a material obligation of Equinet Bank, however, limited to the amount of the typical foreseeable which shall in no event exceed the amount of EUR 10,000. German law shall be applicable and court of jurisdiction for all disputes shall be Frankfurt/Main (Germany).

Competent Supervisory Authority:

Bundesanstalt für Finanzdienstleistungsaufsicht
-BaFin- (Federal Financial Supervisory Authority)
Graurheindorfer Straße 108, 53117 Bonn and
Lurgialle 12, 60439 Frankfurt am Main.



Recommendation history for EUROMICRON AG

Date	Recommendation	Target price	Price at change date
15-Aug-11	Buy	31.50	19.12
27-Apr-11	Buy	30.00	20.76
30-Mar-11	Buy	29.00	18.36
09-Nov-10	Buy	32.00	21.80
12-May-10	Buy	31.00	18.32

Source: Factset & ESN, price data adjusted for stock splits.

This chart shows Equinet Bank continuing coverage of this stock; the current analyst may or may not have covered it over the entire period. Current analyst: Adrian Pehl, CFA (since 28/04/2010)



Price history Target price history
 Buy Accumulate Hold Reduce Sell Not rated



ESN Recommendation System

The ESN Recommendation System is **Absolute**. It means that each stock is rated on the basis of a **total return**, measured by the upside potential (including dividends and capital reimbursement) over a **12 month time horizon**.


The ESN spectrum of recommendations (or ratings) for each stock comprises 5 categories: **Buy, Accumulate (or Add), Hold, Reduce and Sell (in short: B, A, H, R, S)**.

Furthermore, in specific cases and for a limited period of time, the analysts are allowed to rate the stocks as **Rating Suspended (RS)** or **Not Rated (NR)**, as explained below.

Meaning of each recommendation or rating:

- **Buy:** the stock is expected to generate total return of **over 20%** during the next 12 months time horizon
- **Accumulate:** the stock is expected to generate total return of **10% to 20%** during the next 12 months time horizon
- **Hold:** the stock is expected to generate total return of **0% to 10%** during the next 12 months time horizon.
- **Reduce:** the stock is expected to generate total return of **0% to -10%** during the next 12 months time horizon
- **Sell:** the stock is expected to generate total return **under -10%** during the next 12 months time horizon
- **Rating Suspended:** the rating is suspended due to a capital operation (take-over bid, SPO, ...) where the issuer of the document (a partner of ESN) or a related party of the issuer is or could be involved or to a change of analyst covering the stock
- **Not Rated:** there is no rating for a company being floated (IPO) by the issuer of the document (a partner of ESN) or a related party of the issuer

Equinet Bank Ratings Breakdown




History of ESN Recommendation System

Since 18 October 2004, the Members of ESN are using an Absolute Recommendation System (before was a Relative Rec. System) to rate any single stock under coverage.

Since 4 August 2008, the ESN Rec. System has been amended as follow.

- Time horizon changed to 12 months (it was 6 months)
- Recommendations Total Return Range changed as below:



Disclaimer:

These reports have been prepared and issued by the Members of European Securities Network LLP ('ESN'). ESN, its Members and their affiliates (and any director, officer or employee thereof), are neither liable for the proper and complete transmission of these reports nor for any delay in their receipt. Any unauthorised use, disclosure, copying, distribution, or taking of any action in reliance on these reports is strictly prohibited. The views and expressions in the reports are expressions of opinion and are given in good faith, but are subject to change without notice. These reports may not be reproduced in whole or in part or passed to third parties without permission. The information herein was obtained from various sources. ESN, its Members and their affiliates (and any director, officer or employee thereof) do not guarantee their accuracy or completeness, and neither ESN, nor its Members, nor its Members' affiliates (nor any director, officer or employee thereof) shall be liable in respect of any errors or omissions or for any losses or consequential losses arising from such errors or omissions. Neither the information contained in these reports nor any opinion expressed constitutes an offer, or an invitation to make an offer, to buy or sell any securities or any options, futures or other derivatives related to such securities ('related investments'). These reports are prepared for the clients of the Members of ESN only. They do not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive any of these reports. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in these reports and should understand that statements regarding future prospects may not be realised. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in these reports. In addition, investors in securities such as ADRs, whose value are influenced by the currency of the underlying security, effectively assume currency risk.

ESN, its Members and their affiliates may submit a pre-publication draft (without mentioning neither the recommendation nor the target price/fair value) of its reports for review to the Investor Relations Department of the issuer forming the subject of the report, solely for the purpose of correcting any inadvertent material inaccuracies. Like all members employees, analysts receive compensation that is impacted by overall firm profitability. For further details about the specific risks of the company and about the valuation methods used to determine the price targets included in this report/note, please refer to the latest relevant published research on single stock. Research is available through your sales representative. ESN will provide periodic updates on companies or sectors based on company-specific developments or announcements, market conditions or any other publicly available information. Unless agreed in writing with an ESN Member, this research is intended solely for internal use by the recipient. Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or distributed, directly or indirectly, in Australia, Canada or Japan or to any resident thereof. This document is for distribution in the U.K. Only to persons who have professional experience in matters relating to investments and fall within article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005 (the "order") or (ii) are persons falling within article 49(2)(a) to (d) of the order, namely high net worth companies, unincorporated associations etc (all such persons together being referred to as "relevant persons"). This document must not be acted on or relied upon by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.

The distribution of this document in other jurisdictions or to residents of other jurisdictions may also be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report you agree to be bound by the foregoing instructions. You shall indemnify ESN, its Members and their affiliates (and any director, officer or employee thereof) against any damages, claims, losses, and detriments resulting from or in connection with the unauthorized use of this document.

For disclosure upon "conflicts of interest" on the companies under coverage by all the ESN Members and on each "company recommendation history", please visit the ESN website (www.esnpartnership.eu). **For additional information and individual disclaimer please refer to www.esnpartnership.eu and to each ESN Member websites:**

www.bancaakros.it regulated by the CONSOB - Commissione Nazionale per le Società e la Borsa

www.bankiabolso.es regulated by CNMV - Comisión Nacional del Mercado de Valores

www.caixabi.pt regulated by the CMVM - Comissão do Mercado de Valores Mobiliários

www.cmcics.com regulated by the AMF - Autorité des marchés financiers

www.degroof.be regulated by the FSMA - Financial Services and Markets Authority

www.equinet-ag.de regulated by the BaFin - Bundesanstalt für Finanzdienstleistungsaufsicht

www.ibg.gr regulated by the HCMC - Hellenic Capital Market Commission

www.ncb.ie regulated by the Central Bank of Ireland

www.pohjola.com regulated by the Financial Supervision Authority

www.snssecurities.nl regulated by the AFM - Autoriteit Financiële Markten

Members of ESN (European Securities Network LLP)



Banca Akros S.p.A.
Viale Eginardo, 29
20149 Milano
Italy
Phone: +39 02 43 444 389
Fax: +39 02 43 444 302



Equinet Bank AG
Gräfstraße 97
60487 Frankfurt am Main
Germany
Phone: +49 69 – 58997 – 410
Fax: +49 69 – 58997 – 299



Bank Degroof
Rue de l'Industrie 44
1040 Brussels
Belgium
Phone: +32 2 287 91 16
Fax: +32 2 231 09 04



Investment Bank of Greece
24B, Kifisias Avenue
151 25 Marousi
Greece
Phone: +30 210 81 73 000
Fax: +30 210 68 96 325



Bankia Bolsa
Serrano, 39
28001 Madrid
Spain
Phone: +34 91 436 7813
Fax: +34 91 577 3770



NCB Stockbrokers Ltd.
3 George Dock,
Dublin 1
Ireland
Phone: +353 1 611 5611
Fax: +353 1 611 5781



Caixa-Banco de Investimento
Rua Barata Salgueiro, 33-5
1269-050 Lisboa
Portugal
Phone: +351 21 389 68 00
Fax: +351 21 389 68 98



Pohjola Bank plc
P.O.Box 308
FI-00013 Pohjola
Finland
Phone: +358 10 252 011
Fax: +358 10 252 2703



CM - CIC Securities
6, avenue de Provence
75441 Paris
Cedex 09
France
Phone: +33 1 4016 2692
Fax: +33 1 4596 7788



SNS Securities N.V.
Nieuwezijds Voorburgwal 162
P.O.Box 235
1000 AE Amsterdam
The Netherlands
Phone: +31 20 550 8500
Fax: +31 20 626 8064

